Novartis Q3 Operating Profit Falls 61% on Failed Drug Trials

Novartis reported a $2.2 billion loss in Q3, driven by two failed drug trials and higher R&D costs, causing operating profit to drop 61%. The failures raise uncertainty about the company's pipeline and near-term earnings outlook, though the impact is company-specific rather than systemic.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works